Goulding et al. performed a systematic review and meta-analysis demonstrating that KRAS mutational status could be associated with poor prognosis for survival and response outcomes in advanced NSCLC patients [20]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.